Alzamend Neuro Net Worth
Alzamend Neuro Net Worth Breakdown | ALZN |
Alzamend Neuro Net Worth Analysis
Alzamend Neuro's net worth analysis, or its valuation, is the process of determining the total value of the company. This involves assessing a range of factors, including Alzamend Neuro's financial performance, assets, liabilities, and potential for growth. The ultimate goal is to provide a clear understanding of Alzamend Neuro's overall worth, which can help investors make informed investment decisions. There are several methods that can be used to perform Alzamend Neuro's net worth analysis. One common approach is to calculate Alzamend Neuro's market capitalization.Another approach is to use the price-to-earnings ratio (P/E ratio), which compares Alzamend Neuro's stock price to its earnings per share (EPS). Discounted cash flow (DCF) analysis is another popular method for assessing Alzamend Neuro's net worth. This approach calculates the present value of Alzamend Neuro's future cash flows, taking into account factors such as growth rate, profitability, and risk. By comparing the present value of Alzamend Neuro's cash flows to its current stock price, investors can gain a better understanding of the company's overall value. Finally, investors may use comparable company analysis to evaluate Alzamend Neuro's net worth. This involves comparing Alzamend Neuro's financial metrics to similar companies in the same industry. By identifying companies with similar financial characteristics, investors can gain insight into Alzamend Neuro's net worth relative to its peers.
Enterprise Value |
|
To determine if Alzamend Neuro is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Alzamend Neuro's net worth research are outlined below:
| Alzamend Neuro generated a negative expected return over the last 90 days | |
| Alzamend Neuro may become a speculative penny stock | |
| Alzamend Neuro has high historical volatility and very poor performance | |
| Alzamend Neuro has high likelihood to experience some financial distress in the next 2 years | |
| Net Loss for the year was (9.95 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Alzamend Neuro currently holds about 11.53 M in cash with (8.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.12. | |
| Alzamend Neuro has a poor financial position based on the latest SEC disclosures | |
| Latest headline from finance.yahoo.com: Alzamend Neuro Announces Full Data Set from its Nonclinical Study Comparing Brain and Plasma Lithium Exposures between AL001 and Lithium Carbonate in Alzheimers Transgenic Mice |
Alzamend Neuro uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Alzamend Neuro. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Alzamend Neuro's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 31st of January 2024 Next Fiscal Quarter End | View |
Know Alzamend Neuro's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Alzamend Neuro is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Alzamend Neuro backward and forwards among themselves. Alzamend Neuro's institutional investor refers to the entity that pools money to purchase Alzamend Neuro's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Bb&t Corp. | 2024-09-30 | 15.5 K | Parallel Advisors, Llc | 2024-06-30 | 33.0 | Harbor Investment Advisory, Llc | 2024-09-30 | 20.0 | Rfg Advisory Group, Llc | 2024-09-30 | 0.0 | Wells Fargo & Co | 2024-06-30 | 0.0 | Tower Research Capital Llc | 2024-06-30 | 0.0 | Virtu Financial Llc | 2024-06-30 | 0.0 | Advisor Group Holdings, Inc. | 2024-06-30 | 0.0 |
Follow Alzamend Neuro's market capitalization trends
The company currently falls under 'Nano-Cap' category with a current market capitalization of 5.86 M.Market Cap |
|
Project Alzamend Neuro's profitablity
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (15.75) | (14.96) | |
| Return On Capital Employed | 3.83 | 3.64 | |
| Return On Assets | (15.75) | (14.96) | |
| Return On Equity | 3.83 | 3.64 |
When accessing Alzamend Neuro's net worth, it's important to look at multiple sources and consider different scenarios. For example, gross profit margin measures Alzamend Neuro's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Alzamend Neuro's profitability and make more informed investment decisions.
Evaluate Alzamend Neuro's management efficiency
Alzamend Neuro has return on total asset (ROA) of (2.1447) % which means that it has lost $2.1447 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (44.0831) %, meaning that it created substantial loss on money invested by shareholders. Alzamend Neuro's management efficiency ratios could be used to measure how well Alzamend Neuro manages its routine affairs as well as how well it operates its assets and liabilities. As of the 23rd of November 2024, Return On Tangible Assets is likely to grow to -14.96. In addition to that, Return On Capital Employed is likely to drop to 3.64. As of the 23rd of November 2024, Debt To Assets is likely to grow to 0.95, while Net Tangible Assets are likely to drop about 3.3 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (3.84) | (3.65) | |
| Tangible Book Value Per Share | (3.84) | (3.65) | |
| Enterprise Value Over EBITDA | (0.48) | (0.45) | |
| Price Book Value Ratio | (1.85) | (1.95) | |
| Enterprise Value Multiple | (0.48) | (0.45) | |
| Price Fair Value | (1.85) | (1.95) | |
| Enterprise Value | 865.6 M | 702.2 M |
Evaluating the management effectiveness of Alzamend Neuro allows investors to assess its financial health and operational efficiency. Coupled with an analysis of its growth prospects and the current market dynamics, we evaluate the stock's true value and future potential. Key indicators such as revenue, earnings or debt levels are examined alongside external factors like economic trends and regulatory changes. The Alzamend Stock analysis seeks to determine whether the stock is undervalued, appropriately priced, or overvalued, thereby guiding your investment decisions.
Return On Equity (44.08) |
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Alzamend Neuro insiders, such as employees or executives, is commonly permitted as long as it does not rely on Alzamend Neuro's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Alzamend Neuro insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Alzamend Neuro time-series forecasting models is one of many Alzamend Neuro's stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Alzamend Neuro's historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.
Alzamend Neuro Earnings per Share Projection vs Actual
Alzamend Neuro Corporate Management
| Henry Esq | General VP | Profile | |
| Kenneth CPA | Senior Finance | Profile | |
| David Katzoff | Chief Officer | Profile | |
| Stephan Jackman | CEO Director | Profile |
Already Invested in Alzamend Neuro?
The danger of trading Alzamend Neuro is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Alzamend Neuro is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Alzamend Neuro. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Alzamend Neuro is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
When determining whether Alzamend Neuro offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Alzamend Neuro's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Alzamend Neuro Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Alzamend Neuro Stock: Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Alzamend Neuro. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. To learn how to invest in Alzamend Stock, please use our How to Invest in Alzamend Neuro guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alzamend Neuro. If investors know Alzamend will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alzamend Neuro listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (142.87) | Return On Assets (2.14) | Return On Equity (44.08) |
The market value of Alzamend Neuro is measured differently than its book value, which is the value of Alzamend that is recorded on the company's balance sheet. Investors also form their own opinion of Alzamend Neuro's value that differs from its market value or its book value, called intrinsic value, which is Alzamend Neuro's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alzamend Neuro's market value can be influenced by many factors that don't directly affect Alzamend Neuro's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alzamend Neuro's value and its price as these two are different measures arrived at by different means. Investors typically determine if Alzamend Neuro is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alzamend Neuro's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.